

Tomasz StompÅ³r

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4284083/publications.pdf>

Version: 2024-02-01

85
papers

1,220
citations

430874

18
h-index

414414

32
g-index

87
all docs

87
docs citations

87
times ranked

1519
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 mRNA Vaccine-Induced Cellular and Humoral Immunity in Hemodialysis Patients. <i>Biomedicines</i> , 2022, 10, 636.	3.2	6
2	Serum WNT4 protein as an indicator of chronic glomerulonephritis but not a marker of inflammatory cell infiltration and fibrosis: A preliminary study. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 249-259.	1.4	0
3	Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease. <i>Nutrients</i> , 2021, 13, 789.	4.1	7
4	Why albuminuria should be assessed more frequently in everyday clinical practice? Position statement. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 396-406.	0.4	2
5	The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 186.	2.5	3
6	Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization. <i>Toxins</i> , 2021, 13, 274.	3.4	14
7	Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-10.	4.0	12
8	FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. <i>Frontiers in Immunology</i> , 2021, 12, 720183.	4.8	12
9	Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10822.	4.1	66
10	Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. <i>Cardiology Journal</i> , 2021, , .	1.2	0
11	What is the prognostic value of reduced eGFR?. <i>Polski Merkuriusz Lekarski</i> , 2021, 49, 13-18.	0.3	0
12	Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 225-234.	2.9	9
13	Pure Red Cell Aplasia and Antibody-Mediated Rejection: Double Trouble in 1 Kidney Transplant Recipient Solved by Intravenous Immunoglobulin Infusion: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2530-2532.	0.6	2
14	Renalase in chronic kidney disease: the evolving story. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 89-90.	0.4	3
15	Diagnosis and treatment of type 2 diabetes mellitus in patients with chronic kidney disease and eGFR < 60 mL/min ² a position statement of the Polish Society of Nephrology Working Group on Metabolic and Endocrine Disorders in Kidney Diseases. <i>Endokrynologia Polska</i> , 2020, 71, 3-14.	1.0	2
16	Recurrent lower urinary tract infections in adults: don't think it is E. coli, don't choose ciprofloxacin to treat. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 369-370.	0.4	0
17	Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study. <i>Medical Science Monitor</i> , 2020, 26, e921919.	1.1	2
18	What do we know about biomarkers in diabetic kidney disease?. <i>Endokrynologia Polska</i> , 2020, 71, 545-550.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Hypertensive kidney disease: true epidemic or rare disease?. Polish Archives of Internal Medicine, 2020, 130, 130-139.	0.4	14
20	C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. Orphanet Journal of Rare Diseases, 2019, 14, 247.	2.7	10
21	WNT4 Expression in Primary and Secondary Kidney Diseases: Dependence on Staging. Kidney and Blood Pressure Research, 2019, 44, 200-210.	2.0	12
22	Prevalence of Chronic Pain, Particularly with Neuropathic Component, and Its Effect on Overall Functioning of Elderly Patients. Medical Science Monitor, 2019, 25, 2695-2701.	1.1	51
23	Versatility of USP18 in physiology and pathophysiology. Acta Biochimica Polonica, 2019, 66, 389-392.	0.5	4
24	Wyzwania wczesnej diagnostyki szpiczaka plazmocytoowego – algorytm diagnostyczny. Acta Haematologica Polonica, 2019, 50, 121-129.	0.3	0
25	Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease – Position Statement of the Working Group of the Polish Society of Nephrology. Kidney and Blood Pressure Research, 2018, 43, 959-969.	2.0	22
26	Clinicopathologic correlations of renal pathology in the adult population of Poland. Nephrology Dialysis Transplantation, 2017, 32, ii209-ii218.	0.7	28
27	Heparin-induced thrombocytopenia as a cause of prolonged low platelet count in patient with thrombotic thrombocytopenic purpura treated with plasmapheresis. Acta Biochimica Polonica, 2017, 64, 375-376.	0.5	2
28	ZespÅ³Å, metaboliczny wÅ³rÅ³d mÅ™Å¼czyzn z wojewÅ³dztwa warmiÅ„sko-mazurskiego w Polsce. Arterial Hypertension, 2017, 21, 148-152.	0.3	1
29	AktywnoÅ³ fizyczna, nadciÅnienie tÅ™tnicze i obwÅ³d pasa u mÅ™Å¼czyzn z wojewÅ³dztwa warmiÅ„sko-mazurskiego w Polsce. Arterial Hypertension, 2017, 21, 140-147.	0.3	0
30	Endothelial progenitor cells participation in cardiovascular and kidney diseases: a systematic review. Acta Biochimica Polonica, 2016, 63, 475-82.	0.5	24
31	Gout, hyperuricemia and chronic kidney disease: New treatment possibilities. Polish Annals of Medicine, 2016, 23, 195-201.	0.3	6
32	Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland. BMC Nephrology, 2016, 17, 194.	1.8	26
33	Abandonment of internal medicine as a specialty: the point of no return?. Polish Archives of Internal Medicine, 2016, 126, 824-826.	0.4	0
34	Blood pressure and arterial stiffness in patients with high sodium intake in relation to sodium handling and left ventricular diastolic dysfunction status. Journal of Human Hypertension, 2015, 29, 583-591.	2.2	9
35	Acute myocarditis with heart failure in the course of eosinophilic granulomatosis with polyangiitis in a patient on maintenance hemodialysis. Polish Archives of Internal Medicine, 2015, 125, 202-203.	0.4	3
36	Folic acid improves renal function – in what mechanism?. Kardiologia Polska, 2015, 73, 469-469.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Vitamin K in chronic kidney disease: time for a (hint of) hope?. Polish Archives of Internal Medicine, 2015, 125, 618-619.	0.4	0
38	Coronary artery calcification in chronic kidney disease: An update. World Journal of Cardiology, 2014, 6, 115.	1.5	35
39	Long-Term Cholecalciferol Administration in Hemodialysis Patients: A Single-Center Randomized Pilot Study. Medical Science Monitor, 2014, 20, 2228-2234.	1.1	13
40	Unusual manifestation of crystalline light chain tubulopathy in patient with multiple myeloma: case report and review of the literature. Renal Failure, 2014, 36, 795-799.	2.1	5
41	Chronic kidney disease in elderly – Fact or fiction?. Polish Annals of Medicine, 2014, 21, 90-95.	0.3	0
42	Endogenous lithium clearance: a diagnostic method of assessing sodium sensitivity in hypertension. Methodological and clinical implications. Kardiologia Polska, 2014, 72, 1-7.	0.6	1
43	Dual blockade of the renin-angiotensin-aldosterone system in renal disease: what is the future?. Polish Archives of Internal Medicine, 2014, 124, 72-73.	0.4	0
44	High rate of aspirin resistance in advanced kidney failure: does it matter?. Kardiologia Polska, 2014, 72, 401-402.	0.6	0
45	Antibodies against N ^ε -homocysteinylated proteins in patients on different methods of renal replacement therapy. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1093-9.	2.3	1
46	Advanced abdominal arterial calcification sparing kidney allograft – case report. Renal Failure, 2013, 35, 1031-1034.	2.1	0
47	Tamoxifen as the possible cause of severe thromboembolic complications in a patient with a history of renal transplantation and encapsulating peritoneal sclerosis. Polish Archives of Internal Medicine, 2013, 123, 259-261.	0.4	1
48	Osteoporosis in mineral and bone disorders of chronic kidney disease. Polish Archives of Internal Medicine, 2013, 123, 314-320.	0.4	7
49	Kidney and heart: TGF β ¹ -mediated cross-talk. Kardiologia Polska, 2013, 71, 129-129.	0.6	0
50	Can we prolong life of patients with advanced chronic kidney disease: what is the clinical evidence?. Polish Archives of Internal Medicine, 2013, 121, 88-93.	0.4	6
51	Elevated levels of N ^ε -homocysteinyl-lysine isopeptide in patients on long-term hemodialysis. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1373-8.	2.3	4
52	Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 673-682.	6.4	7
53	Renal involvement in multiple myeloma. Polish Archives of Internal Medicine, 2012, 122, 443-448.	0.4	7
54	Renal involvement in multiple myeloma. , 2012, 122, 443-8.		7

#	ARTICLE	IF	CITATIONS
55	Renoprotective effects of benazepril: current perspective. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 663-673.	1.5	3
56	Identifying chronic kidney disease in an emergency department: a chance for an early diagnosis. <i>Polish Archives of Internal Medicine</i> , 2011, 121, 23-28.	0.4	2
57	Can we prolong life of patients with advanced chronic kidney disease: what is the clinical evidence?. , 2011, 121, 88-93.		1
58	The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 522-527.	1.0	17
59	Understanding the variability in Ultrafiltration Obtained with Icodextrin. <i>Peritoneal Dialysis International</i> , 2009, 29, 407-411.	2.3	5
60	Identification of Inflamed Atherosclerotic Plaque using ¹²³ I-Labeled Interleukin-2 Scintigraphy in High-Risk Peritoneal Dialysis Patients: A Pilot Study. <i>Peritoneal Dialysis International</i> , 2009, 29, 568-574.	2.3	11
61	Prevalence and prediction of renal artery stenosis in patients with coronary and supraaortic artery atherosclerotic disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 580-585.	0.7	27
62	An Overview of the Pathophysiology of Vascular Calcification in Chronic Kidney Disease. <i>Peritoneal Dialysis International</i> , 2007, 27, 215-222.	2.3	39
63	Selenium status indices, laboratory data, and selected biochemical parameters in end-stage renal disease patients. <i>Biological Trace Element Research</i> , 2007, 116, 29-41.	3.5	19
64	An overview of the pathophysiology of vascular calcification in chronic kidney disease. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S215-22.	2.3	17
65	Coronary Artery Calcification, Common Carotid Artery Intima-Media Thickness and Aortic Pulse Wave Velocity in Patients on Peritoneal Dialysis. <i>International Journal of Artificial Organs</i> , 2006, 29, 736-744.	1.4	28
66	The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease. <i>Vascular Disease Prevention</i> , 2006, 3, 165-172.	0.2	0
67	Pulse wave velocity and proteins regulating vascular calcification and bone mineralization in patients treated with peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3605-3606.	0.7	6
68	Renal Transplantation Ameliorates the Progression of Arterial Stiffness in Patients Treated with Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2005, 25, 492-496.	2.3	11
69	Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 404-412.	0.7	39
70	Renal transplantation ameliorates the progression of arterial stiffness in patients treated with peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2005, 25, 492-6.	2.3	10
71	Trends and Dynamics of Changes in Aortic Pulse Wave Velocity over One-year Observation Period in Patients Treated with Peritoneal Dialysis. <i>International Journal of Artificial Organs</i> , 2004, 27, 904-906.	1.4	6
72	Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 917-924.	0.7	66

#	ARTICLE	IF	CITATIONS
73	Trends in coronary artery calcification in peritoneal dialysis and transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3205-3206.	0.7	12
74	An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 2003, 41, 203-211.	1.9	154
75	The pharmacokinetics of pioglitazone in patients with impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 368-374.	2.4	125
76	LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 59v-62.	0.7	13
77	An Association between Body Mass Index and Markers of Inflammation: Is Obesity the Proinflammatory State in Patients on Peritoneal Dialysis?. <i>Peritoneal Dialysis International</i> , 2003, 23, 79-83.	2.3	16
78	An Association between Aortic Pulse Wave Velocity, Blood Pressure and Chronic Inflammation in ESRD Patients on Peritoneal Dialysis. <i>International Journal of Artificial Organs</i> , 2003, 26, 188-195.	1.4	30
79	An association between body mass index and markers of inflammation: is obesity the proinflammatory state in patients on peritoneal dialysis?. <i>Peritoneal Dialysis International</i> , 2003, 23, 79-83.	2.3	10
80	Dialysis adequacy, residual renal function and serum concentrations of selected low molecular weight proteins in patients undergoing continuous ambulatory peritoneal dialysis. <i>Medical Science Monitor</i> , 2003, 9, CR500-4.	1.1	5
81	Association between Gastric Emptying Rate and Nutritional Status in Patients Treated with Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2002, 22, 500-505.	2.3	22
82	Selected Growth Factors in Peritoneal Dialysis: Their Relationship to Markers of Inflammation, Dialysis Adequacy, Residual Renal Function, and Peritoneal Membrane Transport. <i>Peritoneal Dialysis International</i> , 2002, 22, 670-676.	2.3	35
83	Association between gastric emptying rate and nutritional status in patients treated with continuous ambulatory peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2002, 22, 500-5.	2.3	6
84	Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. <i>Peritoneal Dialysis International</i> , 2002, 22, 670-6.	2.3	13
85	Angiotensinâ€converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2323-2327.	0.7	23